Skip to main content
Erschienen in: Updates in Surgery 1/2017

17.01.2017 | Original Article

Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis

verfasst von: M. Massani, T. Stecca, C. Ruffolo, N. Bassi

Erschienen in: Updates in Surgery | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Conventional trans-arterial chemoembolization (cTACE) for intermediate stage hepatocellular carcinoma (HCC) achieves a partial response in up to 72% of patients and improves median survival. Drug-eluting-beads-TACE (DEBTACE) improves treatment efficacy and tolerance as compared to cTACE. Our aim was to retrospectively evaluate our experience in the treatment of intermediate/advanced HCC with cTACE versus DEBTACE. Overall survival (OS) was the first endpoint. We retrospectively considered our department register data between 2006 and 2012. A total of 82 non-surgical patients, who underwent cTACE or DEBTACE, with a minimum of 12 months follow-up, met the inclusion criteria. Patients received a standard chemotherapy dose (50 mg). Radiological response was evaluated by CT after 30 days and re-treatment was considered. Statistical analysis was performed with SPSS software. 54 patients received cTACE and 28 DEBTACE. In the DEBTACE group the median survival times was 22.7 months (CI 11.6–33.8), while in the cTACE group it was 21.8 months (CI 15.7–27.9). The survival analysis at log-rank (p = 0.708) and Wilcoxon (p = 0.661) tests demonstrated no differences between DEBTACE and cTACE. The probability of death in function of time was significantly associated only to the Child–Pugh score. A Child A score was shown to be protective instead of Child B (OR 0.583; IC 95% = 0.344–0.987). DEBTACE for treating HCC is comparable to cTACE in terms of effectiveness, but seems to be better tolerated. Both treatments can be performed in case of tumor recurrence without substantial increase in procedural complications and risk of liver failure. We do confirm that there are no differences between the two techniques in terms of survival and that it is mainly affected by the reserved liver function proper of each patient.
Literatur
1.
2.
Zurück zum Zitat Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRefPubMed Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRefPubMed
3.
Zurück zum Zitat Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524CrossRefPubMed Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524CrossRefPubMed
6.
Zurück zum Zitat Mazzaferro V et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–700CrossRefPubMed Mazzaferro V et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–700CrossRefPubMed
7.
Zurück zum Zitat Lammer J et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 33(1):41–52CrossRef Lammer J et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 33(1):41–52CrossRef
8.
Zurück zum Zitat European Association For The Study Of The Liver (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef European Association For The Study Of The Liver (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef
9.
Zurück zum Zitat Angelico M (2016) TACE vs DEB-TACE: Who wins? Digestive and Liver Disease Angelico M (2016) TACE vs DEB-TACE: Who wins? Digestive and Liver Disease
10.
Zurück zum Zitat Facciorusso A et al (2015) Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 7(16):2009CrossRefPubMedPubMedCentral Facciorusso A et al (2015) Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 7(16):2009CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Malagari K et al (2008) Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31:269–280CrossRefPubMed Malagari K et al (2008) Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31:269–280CrossRefPubMed
12.
Zurück zum Zitat Poon RT et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepato 5:1100–1108CrossRef Poon RT et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepato 5:1100–1108CrossRef
13.
Zurück zum Zitat Varela M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481CrossRefPubMed Varela M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481CrossRefPubMed
14.
Zurück zum Zitat Han KH et al (2011) Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 81(Suppl 1):158–164CrossRefPubMed Han KH et al (2011) Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 81(Suppl 1):158–164CrossRefPubMed
15.
Zurück zum Zitat Liapi E, Geschwind J-FH (2011) Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 34:37–49CrossRefPubMed Liapi E, Geschwind J-FH (2011) Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 34:37–49CrossRefPubMed
16.
Zurück zum Zitat Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRef Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRef
17.
Zurück zum Zitat Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
18.
Zurück zum Zitat El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576CrossRefPubMed El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576CrossRefPubMed
19.
Zurück zum Zitat Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed
20.
Zurück zum Zitat El-Serag HB (2011) Hepatocellular carcinoma. N Eng J Med 365:1118–1127CrossRef El-Serag HB (2011) Hepatocellular carcinoma. N Eng J Med 365:1118–1127CrossRef
21.
Zurück zum Zitat Sherman M (2010) Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Seminar Liver Dis 30:3–16CrossRef Sherman M (2010) Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Seminar Liver Dis 30:3–16CrossRef
22.
Zurück zum Zitat Fattovich G et al (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 53:S35–S50CrossRef Fattovich G et al (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 53:S35–S50CrossRef
23.
Zurück zum Zitat Bruno S, Stroffolini T, Colombo M (2007) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45:579–587CrossRefPubMed Bruno S, Stroffolini T, Colombo M (2007) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45:579–587CrossRefPubMed
24.
Zurück zum Zitat Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States form 1975 to 2005. J Clin Oncol 27:1485–1491CrossRefPubMedPubMedCentral Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States form 1975 to 2005. J Clin Oncol 27:1485–1491CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Llovet JM, Di Bisceglie AM, Bruix J (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711CrossRefPubMed Llovet JM, Di Bisceglie AM, Bruix J (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711CrossRefPubMed
26.
Zurück zum Zitat Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRefPubMed Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRefPubMed
27.
Zurück zum Zitat Lewis AL, Gonzales MV, Lloyd AW (2006) DC Bead: in vitro characterisation of a drug-delivery device for transarterial chemoembolisation. J Vasc Interv Radiol 17:335–342CrossRefPubMed Lewis AL, Gonzales MV, Lloyd AW (2006) DC Bead: in vitro characterisation of a drug-delivery device for transarterial chemoembolisation. J Vasc Interv Radiol 17:335–342CrossRefPubMed
28.
Zurück zum Zitat Lewis AL, Gonzalez MV, Leppard SW (2007) Doxorubicin eluting beads. 1. Effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 18:1691–1699CrossRefPubMed Lewis AL, Gonzalez MV, Leppard SW (2007) Doxorubicin eluting beads. 1. Effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 18:1691–1699CrossRefPubMed
29.
Zurück zum Zitat Llovet JM et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRefPubMed Llovet JM et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRefPubMed
30.
Zurück zum Zitat Lo CM et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRefPubMed Lo CM et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRefPubMed
31.
Zurück zum Zitat Hong K, Khwaja A, Liapi E (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–2567CrossRefPubMed Hong K, Khwaja A, Liapi E (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–2567CrossRefPubMed
32.
Zurück zum Zitat Golfieri R, Giampalma E, Renzulli M (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRefPubMedPubMedCentral Golfieri R, Giampalma E, Renzulli M (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Facciorusso A, Mariani L, Sposito C (2016) Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 31:645–653CrossRefPubMed Facciorusso A, Mariani L, Sposito C (2016) Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 31:645–653CrossRefPubMed
34.
Zurück zum Zitat Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol 101:476–480PubMed Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol 101:476–480PubMed
35.
Zurück zum Zitat Song MJ, Chun HJ, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57:1244–1250CrossRefPubMed Song MJ, Chun HJ, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57:1244–1250CrossRefPubMed
36.
Zurück zum Zitat Malagari K et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541–551CrossRefPubMed Malagari K et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541–551CrossRefPubMed
37.
Zurück zum Zitat Sacco R et al (2011) Conventional versus doxorubicin-eluting Bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22:1545–1552CrossRefPubMed Sacco R et al (2011) Conventional versus doxorubicin-eluting Bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22:1545–1552CrossRefPubMed
38.
Zurück zum Zitat Scartozzi M, Baroni GS, Faloppi L, Paolo MD, Pierantoni C, Candelari R (2010) Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res 29:1CrossRef Scartozzi M, Baroni GS, Faloppi L, Paolo MD, Pierantoni C, Candelari R (2010) Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res 29:1CrossRef
39.
Zurück zum Zitat Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, Zheng S, Zhou L (2013) Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 60:813–820PubMed Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, Zheng S, Zhou L (2013) Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 60:813–820PubMed
40.
Zurück zum Zitat Xie ZB, Wang XB, Peng YC (2015) Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res 45:190–200CrossRefPubMed Xie ZB, Wang XB, Peng YC (2015) Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res 45:190–200CrossRefPubMed
41.
Zurück zum Zitat Song MJ et al (2011) Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 23:521–527CrossRefPubMed Song MJ et al (2011) Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 23:521–527CrossRefPubMed
42.
Zurück zum Zitat Cuchetti A, Trevisani F, Cappelli A, Mosconi C, Renzulli M, Pinna AD, Golfieri R (2016) Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis. 48(7):798–805CrossRef Cuchetti A, Trevisani F, Cappelli A, Mosconi C, Renzulli M, Pinna AD, Golfieri R (2016) Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis. 48(7):798–805CrossRef
Metadaten
Titel
Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis
verfasst von
M. Massani
T. Stecca
C. Ruffolo
N. Bassi
Publikationsdatum
17.01.2017
Verlag
Springer Milan
Erschienen in
Updates in Surgery / Ausgabe 1/2017
Print ISSN: 2038-131X
Elektronische ISSN: 2038-3312
DOI
https://doi.org/10.1007/s13304-017-0414-3

Weitere Artikel der Ausgabe 1/2017

Updates in Surgery 1/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.